Dementia
Recent clinical, regulatory, research and industry developments relating to this disease.
Life's End Benefits of cannaBidiol and tetrahYdrocannabinol (LiBBY)
A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia.
Genomic Insights into Dementia: Precision Medicine and the Impact of Gene-Environment Interaction.
Inflammation unites diverse acute and chronic diseases.
Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia.
Severe psychiatric disorders are associated with increased risk of dementia.
Metformin, Cognitive Function, and Changes in the Gut Microbiome.
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 6 clinical trials expected to report results, the earliest in Q4 2028.
- 12 industry developments reported.
- Q4 2028AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)
- Q2 2029A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
- Q2 2029A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above
- Q2 2029A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline
- Q3 2029An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM
Clinical MilestonesView all 14Hide
- 2026-04-16Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's DiseaseResults posted
- 2026-02-24A Randomised Double-blind Placebo-controlled Clinical Study Investigating the Effects of Semaglutide s.c. Once-weekly Versus Placebo on Central and Peripheral Inflammation in Participants With Alzheimer's DiseaseResults posted
- 2026-10-14A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or AboveResults expected Q2 2029
- 2026-10-07A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional DeclineResults expected Q2 2029
- 2026-07-27The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer's DiseaseResults expected Q2 2030
- 2026-07-07An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACMResults expected Q3 2029
- 2026-06-04AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)Results expected Q4 2028
- 2026-05-12Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's DiseaseCompleted
- 2026-01-30A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus)Completed
- 2026-01-30A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)Completed
- 2026-04-01Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's DiseaseWithdrawn
- 2026-03-11Long-term Extension of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 GenotypeTerminated
- 2026-01-06A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin GeneTerminated
Industry & MarketView all 12Hide
- 2026-10-23<![CDATA[FDA Aligns on Key Elements of Phase 3 Study of Zervimesine for Dementia With Lewy Bodies ]]>Regulatory news · Psychiatric Times
- 2026-11-03Brain Injury Creates Musical Genius; Long COVID Improvement; Dementia and DeliriumIndustry · MedPage Today — Neurology
- 2026-11-02Extreme Heat Tied to Higher Dementia Risk in Adults Aged 50+Industry · Medscape Medical News
- 2026-10-29Less than 42 minutes of bright daylight linked to higher dementia riskIndustry · Science Daily
- 2026-10-26Urban living and dementia risk: associations with perceived green space qualities and traffic noise annoyanceIndustry · Nature — Environmental Sciences
- 2026-11-03IndustryBrain Injury Creates Musical Genius; Long COVID Improvement; Dementia and DeliriumIndustry · MedPage Today — Neurology
- 2026-11-02IndustryExtreme Heat Tied to Higher Dementia Risk in Adults Aged 50+Industry · Medscape Medical News
- 2026-10-30IndustryPatrick Stewart's Death Highlights Lewy Body DementiaIndustry · MedPage Today — Neurology
- 2026-10-29Industry<![CDATA[Neflamapimod for Dementia With Lewy Bodies Misses End Point, Subgroup Signal Emerges]]>Industry · Psychiatric Times
- 2026-10-29IndustryLess than 42 minutes of bright daylight linked to higher dementia riskIndustry · Science Daily
- 2026-10-27IndustryHead Shape and Alzheimer's; Prenatal Choline and Kids' IQ; Aspirin and DementiaIndustry · MedPage Today — Neurology
- 2026-10-27Industry<![CDATA[Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia]]>Trial news · Psychiatric Times
- 2026-10-26IndustryUrban living and dementia risk: associations with perceived green space qualities and traffic noise annoyanceIndustry · Nature — Environmental Sciences
- 2026-10-25IndustryLow-dose aspirin linked to 70% lower dementia risk, but there's a catchIndustry · Science Daily
- 2026-10-23Industry<![CDATA[FDA Aligns on Key Elements of Phase 3 Study of Zervimesine for Dementia With Lewy Bodies ]]>Regulatory news · Psychiatric Times
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Original application approval — Donanemab is indicated for the treatment of adult patients with a clinical diagnosis of m… (2025)
Original application approval — Leqembi is indicated for the treatment of adult patients with a clinical diagnosis of mil… (2025)
Original application approval — Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic trea… (2009)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Dementia9
- Diabetes Mellitus, Type 23
- Cardiovascular Diseases2
- Life Style2
- Parkinson Disease2
- Stroke2
- Blood Proteins1
- Brain1
Leading journals6
- JAMA2
- JAMA network open2
- Aging and disease1
- Alzheimer's & dementia : the journal of the Alzheimer's Association1
- Behavioural neurology1
- BMC medicine1
Leading researchers8
- Molinuevo JL2
- Scheltens P2
- Soininen H2
- Aalten P1
- Aarsland D1
- Adena MA1
- Albert M1
- Alcolea D1
Affiliations (unnormalised)6
- School of Public Health3
- Memory and Aging Center2
- School of Medicine2
- University of California2
- University of Pennsylvania2
- Aging Research Center1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Dementia is an acquired organic mental disorder marked by loss of intellectual abilities severe enough to interfere with social or occupational functioning. It involves multiple domains of cognition, including memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The decline is usually progressive and initially spares consciousness.
The grounding supports dementia as a multifactorial condition with contributions from advanced age, genetic, socioeconomic, environmental, nutritional, and physical-activity-related determinants. It also links type 2 diabetes with increased risk of cognitive impairment and dementia. Cerebral amyloid-β aggregation is described as an early pathological event in Alzheimer disease that begins decades before dementia onset, but the grounding does not support this as a universal cause of dementia.
The literature grounding describes dementia in the context of progressive cognitive decline and age-related brain changes affecting brain size, vasculature, neurotransmitters, hormones, and cognition. It also notes that cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease before dementia onset. Beyond this, the supplied material does not support a single unified biological mechanism for dementia.
Advanced age is identified as the main independent risk factor for cognitive impairment and dementia. Other supported risk factors or associated determinants include genetic, socioeconomic, and environmental factors, as well as nutrition and physical inactivity. Type 2 diabetes is also linked to increased risk of cognitive impairment and dementia.
The grounding supports nonpharmacologic management centered on prevention and supportive interventions, especially physical activity, aerobic exercise, healthy diet, and broader lifestyle modification. It also notes that there are no hitherto effective pharmaceutical therapies for age-associated cognitive impairment and dementia in the reviewed literature. Drug therapy is mentioned as a literature aspect, but the supplied abstracts do not support a specific standard drug-class treatment for dementia.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.